LOGIN  |  REGISTER
Cue Biopharma
Amneal Pharmaceuticals

Registration Is Now Open For Tribe Public's Webinar Event "Diabetes Care For The Rest Of Us." Featuring Modular Medical CEO On Friday, December 15, 2023

December 11, 2023 | Last Trade: US$2.07 0.07 -3.27
  • Meet with Modular Medical CEO, Jeb Besser
  • There are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US. 100% of patient population require daily insulin injection. Only 20% currently use an insulin pump.
  • Discover how Modular Medical is developing technology to empower the community of people with diabetes by offering a simple yet effective Insulin delivery device, MODD1

SAN DIEGO, CA / ACCESSWIRE / December 11, 2023 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that Jeb Besser, CEO, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Diabetes Care For The Rest Of Us." The event is scheduled to begin at 8:30am pacific/11:30am eastern on Friday, December 15, 2023. To register to join the complimentary event, please visit the Tribe Public LLC at MODD121523.TribePublic.com.

Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at This email address is being protected from spambots. You need JavaScript enabled to view it.or share their questions via the ZOOM chat feature during the event. Tribe Public's Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.

About Modular Medical

Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."

Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

All trademarks mentioned herein are the property of their respective owners.

ABOUT TRIBE PUBLIC LLC

Tribe Public LLC is a San Francisco, CA based organization that hosts complimentary worldwide webinar & meeting events in the U.S. Tribe's complimentary events focus on issues that the Tribe members care about with an emphasis on hosting management teams from publicly traded companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress and plans. Tribe members primarily include Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media. Tribe Members are encouraged to express their interest in speakers they care about and want to learn from at the Tribe Public website via the Tribe's FREE "Wish List" process. Visit Tribe Public's Website to learn more: http://www.tribepublic.com/

CONTACT:

Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB